Loading
A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting.
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06970847 by Clarity Pharmaceuticals Ltd, with 220 participants enrolled, started 2025-05-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: 64Cu-SAR-bisPSMA.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.